Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197179 | 1.00 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL2199586 | 0.85 | PPM1D (0.32) | — | |
| SCHEMBL2197519 | 0.75 | CHRM2 (0.35) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL2197525 | 0.75 | CHRM2 (0.35) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL2194353 | 0.72 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL2194350 | 0.72 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL2147642 | 0.71 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL2147645 | 0.71 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL29428649 | 0.71 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREPUSP2 | |
| SCHEMBL26196651 | 0.71 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREPUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152713-B1 | PYRAZOLOPYRROLIDINES AS INHIBITORS OF GAMMA SECRETASE | ELAN PHARM INC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7977368-B2 | Pyrazolopyrrolidines as inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977368-B2 | Pyrazolopyrrolidines as inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099235-A1 | Pyrazolopyrrolidines as Inhibitors of Gamma Secretase | BACE1, BACE2, APP | CHRM2 30/4885CHRM1 36/4885CHRM3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.